Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)

This study has been completed.
Sponsor:
Collaborator:
Integrated Therapeutics Group
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00367237
First received: August 18, 2006
Last updated: May 6, 2014
Last verified: May 2014
  Purpose

This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic arthritis patients.


Condition Intervention Phase
Arthritis, Psoriatic
Drug: Infliximab + methotrexate (IFX + MTX)
Drug: Methotrexate (MTX)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16 [ Time Frame: between baseline and week 16 ] [ Designated as safety issue: No ]
    >=20% improvement in swollen and tender joint count AND >=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.


Secondary Outcome Measures:
  • Proportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable [ Time Frame: between baseline and week 16 ] [ Designated as safety issue: No ]
    This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

  • Change in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ) [ Time Frame: between baseline and week 16 ] [ Designated as safety issue: No ]
    This is not a prespecified key secondary outcome; therefore, results will not be disclosed.

  • Adverse Events [ Time Frame: between baseline and week 16 ] [ Designated as safety issue: Yes ]
    This is not a prespecified key secondary outcome; therefore, results will not be disclosed.


Enrollment: 115
Study Start Date: May 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Infliximab + methotrexate (IFX + MTX)
Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
Drug: Infliximab + methotrexate (IFX + MTX)
Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
Other Name: Group 1, Remicade + MTX
Active Comparator: Methotrexate (MTX)
Oral methotrexate (MTX) 15 mg/week
Drug: Methotrexate (MTX)
Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
Other Name: Group 2, MTX

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject must meet ALL of the criteria listed below for entry into the study:
  • Subject must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
  • Subject aged 18 years or more, of either sex and any race
  • Diagnosis of Psoriatic Arthritis with peripheral polyarticular involvement. Patients will have at least one of the following:

    • Distal Interphalangeal Joints (DIP) involvement
    • polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis
    • arthritis mutilans
    • asymmetric peripheral arthritis
  • Negative rheumatoid factor
  • The disease should have been diagnosed at least 3 months prior to screening.
  • Active disease at the time of screening and prior to receiving the baseline study medication(s) as defined by:

    • 5 or more swollen joints and
    • 5 or more tender joints
    • and one out of the following three categories:

      • Erythrocyte Sedimentation Rate (ESR) >= 28 mm/h
      • C-reactive protein (CRP) >= 15 mg/l
      • Morning stiffness >= 45 min
  • Subjects must confirm that they are practicing adequate contraception: Female subjects of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male and female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g., hysterectomy or tubal ligation).
  • Female subjects of childbearing potential must have a negative pregnancy test at Screening.
  • Subjects must be eligible for anti-tumor necrosis factor (TNF) treatment according to applicable local guidelines. For all patients chest X-ray and skin test results must be available at baseline.
  • If using Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids other than i.v., i.m. or i.a., the patient must be on a stable dose for four weeks prior screening (maximum dose up to 10mg/day of prednisone or its oral equivalent).
  • The screening laboratory tests must beet the following criteria:

    • Hemoglobin >= 10 g/dl providing the low hemoglobin level is not due to other diseases than anemia of chronic inflammation.
    • white blood cell (WBC) >= 3500 / μl
    • Neutrophils >= 1500 / μl
    • Platelets >= 100 000/ μl
    • Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase <= 1.5 x upper limit of normal
    • Total bilirubin <= 1 x upper limit of normal
    • Serum creatinine <= 1.5 mg/dl
  • Patient must be able to adhere to the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures.

Exclusion Criteria:

  • The subject will be excluded from entry into the study if ANY of the criteria listed below are met:
  • Subject is a female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
  • Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis.
  • Previous treatment with Infliximab.
  • Subjects who have previously received MTX or have not discontinued their other DMARD therapy (i.e., sulfasalazine, hydroxychloroquine, leflunomide).
  • Patients with fibromyalgia syndrome.
  • Use of cyclosporine or tacrolimus within 4 weeks prior to screening. Use of IM, IV, or IA corticosteroids within 4 weeks prior to screening.
  • Treatment with any investigational drug within 3 months prior to screening.
  • Previous treatment with a monoclonal antibody or a fusion protein.
  • A history of known allergy to murine proteins.
  • History of infected joint prosthesis within the previous 5 years.
  • Chronic infections.
  • History of active tuberculosis requiring treatment within previous 3 years or history of opportunistic infections within 2 months, uncontrolled active infection or documented HIV infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis without documented adequate therapy, if they will not be treated according to local tuberculosis (TB) guidelines.
  • Subject has any clinically significant deviation from normal in the physical examination, chest X-ray, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the study evaluation or affect subject safety.
  • Current signs or symptoms of other severe uncontrolled diseases, which in the investigators opinion would put the patient at an unacceptable risk.
  • History of lymphoproliferative disease, any current malignancies or history of malignancy within 5 years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin.
  • Subject is part of the staff or a family member of the staff personnel directly involved with this study.
  • History of drug abuse.
  • Subjects who are participating in any other clinical study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided by Merck Sharp & Dohme Corp.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00367237     History of Changes
Other Study ID Numbers: P04422, EUDRACT #: 2005-002189-12
Study First Received: August 18, 2006
Results First Received: March 19, 2009
Last Updated: May 6, 2014
Health Authority: Russia: Pharmacological Committee, Ministry of Health
Estonia: The State Agency of Medicine
Lithuania: State Medicine Control Agency - Ministry of Health
Egypt: Ministry of Health and Population
Israel: Israeli Health Ministry Pharmaceutical Administration
Poland: Ministry of Health
Slovakia: State Institute for Drug Control
Hungary: National Institute of Pharmacy
Romania: State Institute for Drug Control
Bulgaria: Ministry of Health
Croatia: Ministry of Health and Social Care
Slovenia: Agency for Medicinal Products - Ministry of Health
Turkey: Ministry of Health
South Africa: National Health Research Ethics Council
Qatar: Hamad Medical Corporation, Rheumatology Divison-Doha

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Infliximab
Methotrexate
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Dermatologic Agents
Gastrointestinal Agents
Central Nervous System Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents

ClinicalTrials.gov processed this record on October 19, 2014